Merck, Hansoh Pharma Enter Exclusive Global License Agreement For HS-10535, An Investigational Preclinical Oral Small Molecule GLP-1 Receptor Agonist; Hansoh To Receive An Upfront Payment Of $112M And Up To $1.9B In Milestones
Merck, Hansoh Pharma Enter Exclusive Global License Agreement For HS-10535, An Investigational Preclinical Oral Small Molecule GLP-1 Receptor Agonist; Hansoh To Receive An Upfront Payment Of $112M And Up To $1.9B In Milestones
Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as royalties on sales.
根據該協議，漢森製藥已授予默沙東開發、製造和商業化 HS-10535 的全球獨家許可。Hansoh Pharma將獲得1.12億美元的預付款，並有資格獲得與候選人的開發、監管批准和商業化相關的高達19億美元的里程碑付款，以及銷售特許權使用費。
Hansoh Pharma may co-promote or solely commercialize HS-10535 in China subject to certain conditions. Merck will record a pre-tax charge of $112 million, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.
Hansoh Pharma 可以在中國共同推廣或單獨將 HS-10535 商業化，但須遵守某些條件。默沙東將記錄1.12億美元的稅前費用，合每股0.04美元，將計入2024年第四季度的公認會計准則和非公認會計准則業績。
